biotech / news / / Hindustan Times
Sun Pharmaceutical Industries on Monday announced the $11.75 billion acquisition of Organon & Co. US contributes about 31% of Sun’s revenues, second only to the Indian domestic market bringing 37%.
Sun Pharma's $11.75 billion Organon acquisition is the largest Indian pharma deal in two decades.
KEY POINTS
- The combined entity’s US revenue share drops to 27%, while India’s share falls to 17%.
- The acquisition targets geographic diversification, notably expanding Sun Pharma's presence in China and South Korea.
- Sun Pharma gains immediate access to Organon's scale in Spain and branded generics portfolios for cross-selling.
- The US generics market is declining in profitability due to pricing pressure and structural shift toward biologics.
COMPANIES
Summarized by Newsio from Hindustan Times. How we summarize →